<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nada Alachkar, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andre A Kaplan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher H Kwoh, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christophe Legendre, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 12, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2304884220"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Focal segmental glomerulosclerosis (FSGS) is a histologic pattern of injury in the kidney that may have different etiologies, including genetic diseases, infection, toxins, and obesity, as well as previous injury resulting in hyperfiltration of remaining viable nephrons.</p><p>Primary FSGS, which occurs in the absence of a known etiology, commonly progresses to end-stage kidney disease (ESKD). When kidney transplantation is performed, primary FSGS may recur in the kidney allograft.</p><p>An overview of FSGS in the kidney allograft is presented in this topic review. The pathogenesis, classification, clinical features, diagnosis, and treatment of FSGS in the native kidney are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H584887072"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Focal segmental glomerulosclerosis (FSGS) may be recurrent or de novo. The following definitions will be used in this topic review:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent FSGS</strong> – Recurrent FSGS refers to the development of primary FSGS in the transplanted kidney in patients with primary FSGS as the cause of end-stage kidney disease (ESKD) in the native kidneys. Less commonly, FSGS may recur in patients with certain forms of genetic FSGS (eg, those with podocin mutations).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>De novo FSGS</strong> – De novo FSGS is the development of primary or secondary FSGS in the transplanted kidney in patients who did not have FSGS in their native kidneys.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary FSGS</strong> – Primary FSGS refers to FSGS that is caused by a putative circulating factor that is toxic to the podocyte and results in generalized podocyte dysfunction. (See  <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis", section on 'Pathogenesis of primary FSGS'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary FSGS</strong> – Secondary FSGS generally occurs as an adaptive phenomenon that results from a reduction in nephron mass or direct toxicity from drugs or viral infections. (See  <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis", section on 'Pathogenesis of secondary FSGS'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic FSGS</strong> – Genetic FSGS refers to FSGS that is caused by a number of genetic mutations in genes that code for proteins expressed in podocytes and at the slit diaphragm. (See  <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">"Focal segmental glomerulosclerosis: Genetic causes"</a>.)</p><p></p><p class="headingAnchor" id="H3655473512"><span class="h1">RECURRENT FSGS</span></p><p class="headingAnchor" id="H3174441184"><span class="h2">Epidemiology and risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The rate of recurrent primary focal segmental glomerulosclerosis (FSGS) is difficult to ascertain since it is often not clear whether the patient had primary or secondary FSGS as the initial cause of end-stage kidney disease (ESKD) [<a href="#rid1">1-13</a>]. The best data come from the multicenter Post-Transplant Glomerular Disease (TANGO) cohort study of 11,742 adult kidney transplant recipients, 176 of whom had a biopsy-proven diagnosis of primary FSGS [<a href="#rid1">1</a>]. FSGS recurred in 57 patients (32 percent), with most recurrences occurring early after transplantation (median time to recurrence 1.5 months).</p><p></p><p class="bulletIndent1">Other causes of FSGS, including infection, toxins, or obesity, may occur in the allograft but are uncommon, at least in patients for whom the cause of FSGS in the native kidney is known. In general, the conditions that caused FSGS in the native kidney are treated prior to transplantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for recurrence</strong> – Several risk factors for recurrence of FSGS posttransplantation have been reported, including younger age of disease onset, rapid progression of initial disease, being White, prior native kidney nephrectomy, lower body mass index (BMI) at transplantation, and a history of recurrence in a prior allograft [<a href="#rid1">1,14-17</a>]. In the United States, White recipients of African-American kidneys may be at particularly high risk of recurrence [<a href="#rid9">9</a>]. On the other hand, Black recipients appear to represent a lower risk group, in which recurrence is less frequent [<a href="#rid6">6,9</a>].</p><p></p><p class="bulletIndent1">A family history of FSGS generally predicts a lower risk of recurrence [<a href="#rid18">18,19</a>]. However, the risk of recurrence of familial FSGS may depend upon the specific mutation. Recurrent disease has been reported among patients with podocin mutations [<a href="#rid19">19-24</a>] and in one patient with a <em>TRPC6</em> mutation [<a href="#rid25">25</a>]. Variants of the <em>MYH9</em> and <em>APOL1</em> genes, which are prevalent among African Americans, are highly associated with an increased risk of developing FSGS in the native kidney [<a href="#rid26">26-30</a>]; however, recipients with <em>MYH9</em> and <em>APOL1</em> high-risk alleles do not have an increased risk of recurrent FSGS in the allograft. While an earlier study found no association between <em>APOL1 </em>high-risk alleles and allograft survival [<a href="#rid31">31</a>], two subsequent studies have shown that patients with two <em>APOL1 </em>high-risk alleles may have an increased risk of allograft loss compared with those with only one or no high-risk alleles [<a href="#rid32">32,33</a>]. (See  <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">"Focal segmental glomerulosclerosis: Genetic causes", section on 'FSGS in Black patients'</a>.)</p><p></p><p class="bulletIndent1">Histologic subtype of FSGS in the native kidney [<a href="#rid34">34,35</a>], human leukocyte antigen (HLA) mismatch [<a href="#rid17">17</a>], and choice of transplantation immunosuppressive therapy [<a href="#rid25">25,36,37</a>] have not been shown to alter the risk of recurrence.</p><p></p><p class="headingAnchor" id="H3368387076"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Recurrent primary FSGS is likely due to a circulating factor or the absence of a normal factor present in plasma, with either resulting in toxicity to the podocyte or glomerular capillary wall.</p><p>Several reports support this hypothesis [<a href="#rid38">38-44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum from some patients with FSGS increases the permeability of isolated glomeruli to albumin. The ability of pretransplant serum to increase in vitro glomerular permeability may predict FSGS recurrence after transplantation [<a href="#rid38">38,39</a>]. As an example, in one study, the incidence of recurrence was 86 percent (six of seven) when glomerular permeability to albumin was substantially increased by exposure to patient serum [<a href="#rid38">38</a>]. By contrast, the incidence of recurrence was only 17 percent (4 of 19) among patients whose serum did not increase in vitro glomerular permeability. These findings also suggest that the permeability factor may be specific to only certain types of FSGS that are more likely to recur in the transplanted kidney.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of a regenerating protein adsorption column or plasma exchange can reduce protein excretion in a subgroup of patients with recurrent FSGS  (<a class="graphic graphic_figure graphicRef51857" href="/z/d/graphic/51857.html" rel="external">figure 1</a>) [<a href="#rid40">40</a>]. The factor that is removed increased protein excretion when injected into rats.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More prolonged remissions have been achieved using standard plasmapheresis that is initiated promptly after the onset of proteinuria [<a href="#rid41">41</a>] or the combination of plasmapheresis and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Indirect support for a circulating recipient factor is provided by case reports, in which a kidney transplant recipient developed recurrent FSGS with marked proteinuria and foot process effacement on biopsy [<a href="#rid45">45-47</a>]. Upon removal of the kidney and retransplantation into a second recipient, there was almost complete resolution of proteinuria and reversal of histologic lesions. </p><p></p><p>The identity of the circulating permeability factor is not known with certainty, although the serum soluble urokinase plasminogen activator receptor (suPAR), apolipoprotein A1 (apoA-1), C-C motif chemokine ligand (CCL), anti-CD40 autoantibody, and anti-nephrin antibody are possible causative factors [<a href="#rid48">48-52</a>]. It is probable that additional factors exist. The potential role of suPAR in the pathogenesis of FSGS is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis", section on 'suPAR'</a>.)</p><p>In some cases of recurrent FSGS, tumor necrosis factor (TNF)-alpha pathway activation was found to be the cause of the recurrence, suggesting that TNF-alpha blockade could be a potential targeted therapy [<a href="#rid53">53-55</a>].</p><p class="headingAnchor" id="H3387592073"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Patients with recurrent primary FSGS typically present with the rapid onset of proteinuria, which is frequently in the nephrotic range [<a href="#rid2">2</a>]. Increased protein excretion may be noted in the immediate to early posttransplantation period; in children, the median time to recurrent proteinuria is approximately 10 to 14 days after transplantation [<a href="#rid6">6,36</a>], while in adults, the median time to recurrence is approximately 1.5 months [<a href="#rid1">1,56</a>]. Less commonly, patients with recurrent primary FSGS may present later (several months or years) after transplantation.</p><p>Patients usually have symptoms and signs of nephrotic syndrome, including edema, hypoalbuminemia, and hyperlipidemia [<a href="#rid2">2,6,36</a>], and many patients have decreased allograft function. Some patients develop anasarca (ie, generalized and massive edema), with marked peripheral edema, abdominal distension resulting from ascites, marked scrotal or vulvar edema, and severe periorbital edema resulting in swollen-shut eyelids. Patients usually do not have gross hematuria, although microscopic hematuria may be present. (See  <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a> and  <a class="medical medical_review" href="/z/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome"</a>.)</p><p class="headingAnchor" id="H2669048856"><span class="h2">Screening and diagnosis</span></p><p class="headingAnchor" id="H2674211605"><span class="h3">Posttransplantation surveillance</span><span class="headingEndMark"> — </span>To help detect early recurrence posttransplantation, all patients with primary FSGS as the cause of ESKD in the native kidneys should be screened for proteinuria. We obtain a random or spot urine protein-to-creatinine ratio on the first postoperative day, the day of scheduled hospital discharge, weekly for four weeks, and then monthly for one year after transplantation [<a href="#rid57">57</a>]. If the ratio is &gt;0.5 g/g, we obtain a 24-hour protein collection to confirm the result obtained with the random urine protein-to-creatinine ratio.</p><p>Protein excretion from native kidneys decreases significantly within one month of transplantation; thus, proteinuria that is detected more than one month after transplantation is most likely derived from the allograft and should trigger further investigation [<a href="#rid58">58,59</a>]. A kidney biopsy to exclude other causes of proteinuria should be performed if posttransplantation proteinuria exceeds 1 g/day and should include electron microscopy to detect early features of FSGS. (See <a class="local">'Diagnostic evaluation'</a> below and  <a class="medical medical_review" href="/z/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction", section on 'Patients presenting with proteinuria'</a>.)</p><p>The rationale underlying aggressive screening is that recurrent primary FSGS may result in the rapid development of nephrotic syndrome with numerous sequelae, including massive volume overload, acute kidney injury (AKI), thrombosis, and hyperlipidemia. In addition, recurrent primary FSGS commonly leads to allograft loss. Although the efficacy of immunomodulatory therapies for recurrent FSGS is unproven, early institution of therapy is believed to be more likely to be effective than delayed treatment. (See <a class="local">'Treatment'</a> below and <a class="local">'Prognosis'</a> below.)</p><p>To ensure the ability to detect recurrent proteinuria following transplantation, some have advocated that patients with significant proteinuria of the native kidney should undergo pretransplantation medical nephrectomy (with an angiotensin-converting enzyme [ACE] inhibitor, angiotensin II receptor blocker [ARB], or nonsteroidal antiinflammatory drug [NSAID]), renal ablation, or surgical nephrectomy [<a href="#rid57">57</a>]. Secondary native ureteral ligation is also possible in case of doubt to avoid unnecessary treatment to the patient [<a href="#rid60">60</a>]. However, we believe that nephrectomy is probably only warranted for massive, refractory proteinuria (ie, resulting in clinically debilitating hypoalbuminemia), especially associated with malnutrition in children with such disorders as congenital nephrotic syndrome.</p><p>Other biomarkers, such as urinary apoA-1b [<a href="#rid61">61,62</a>], have been proposed to predict recurrent primary FSGS, but further investigation is required.</p><p class="headingAnchor" id="H3494044213"><span class="h3">Diagnostic evaluation</span><span class="headingEndMark"> — </span>The diagnosis of recurrent FSGS should be suspected in any patient with primary FSGS as the cause of ESKD in the native kidneys who presents with proteinuria greater than 1 g/day detected by routine screening (see <a class="local">'Posttransplantation surveillance'</a> above) or who develops symptoms and signs of nephrotic syndrome. Such patients should undergo a kidney allograft biopsy to confirm the diagnosis of FSGS. Patients who are diagnosed with FSGS by allograft biopsy should be evaluated for possible underlying causes and associated conditions, since clinical and histologic features alone cannot distinguish recurrent primary from de novo secondary FSGS with certainty.</p><p class="headingAnchor" id="H1622956749"><span class="h4">Kidney biopsy</span><span class="headingEndMark"> — </span>A definitive diagnosis of recurrent FSGS in the kidney allograft is made based upon kidney biopsy findings in the setting of significant proteinuria (&gt;1 g/day). Allograft histology typically demonstrates characteristic features of FSGS that are identical to FSGS in the native kidney. However, a kidney biopsy early in the disease course may show no significant changes by light microscopy and may only reveal diffuse podocyte foot process effacement (if electron microscopy is performed), a finding that precedes the development of sclerotic lesions [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis", section on 'Pathology'</a>.)</p><p>Five histologic patterns of FSGS have been recognized, which are associated with different clinical manifestations and prognoses. It is not clear whether the histologic subtype observed in recurrent FSGS is generally the same subtype as that observed in the native kidney [<a href="#rid34">34,35,63</a>]. The histologic subtype of FSGS in the native kidney has not been shown to predict recurrence posttransplantation. (See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis", section on 'Histologic variants'</a>.)</p><p class="headingAnchor" id="H3718222428"><span class="h4">Evaluation for secondary causes</span><span class="headingEndMark"> — </span>Once the diagnosis of FSGS is confirmed by kidney allograft biopsy, an evaluation for causes of secondary FSGS  (<a class="graphic graphic_table graphicRef118939" href="/z/d/graphic/118939.html" rel="external">table 1</a>) should be performed since histologic features do not reliably distinguish between primary and secondary FSGS, and there is significant overlap in the clinical features. This is particularly relevant for patients with recurrent FSGS who present with a later onset (ie, &gt;3 months) after transplantation since differentiating between recurrent primary FSGS and de novo secondary FSGS may be challenging in such patients. (See <a class="local">'Later recurrence (&gt;3 months posttransplantation)'</a> below and <a class="local">'De novo FSGS'</a> below.)</p><p>The evaluation includes the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Tests for parvovirus B19, cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK polyomavirus (BKPyV), hepatitis C virus (HCV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [<a href="#rid64">64,65</a>], and if risk factors are present, HIV. (See  <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">"Clinical manifestations and treatment of Epstein-Barr virus infection", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/7338.html" rel="external">"Kidney transplantation in adults: BK polyomavirus-associated nephropathy", section on 'Screening and diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection", section on 'Initial testing'</a> and  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection", section on 'Testing algorithm'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A review of the patient's medications, looking for potentially causative agents, such as mammalian (mechanistic) target of rapamycin (mTOR) inhibitors, bisphosphonates, interferon, heroin, and anabolic steroids. (See  <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis", section on 'Drugs and toxins'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of BMI.</p><p></p><p>In addition, some experts evaluate all patients with recurrent FSGS for hypogammaglobulinemia, which is associated with viral infections that may cause FSGS and has been observed in recipients of solid organ transplants [<a href="#rid66">66,67</a>]. Other experts, however, only evaluate for hypogammaglobulinemia among patients who are undergoing plasmapheresis, which is used for the treatment of recurrent primary FSGS, in order to ascertain that patients are receiving adequate repletion of antibodies that are removed during plasmapheresis sessions. (See <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H446814731"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>In patients with primary FSGS as the cause of ESKD in the native kidneys, we do not administer any prophylactic measures to prevent recurrent FSGS. Although such patients may be at high risk of recurrence, the use of preventive measures (such as plasmapheresis or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) in these patients has not been clearly shown to reduce rates of recurrence. Although data from case reports and small case series initially suggested that preemptive plasmapheresis lowers the risk of recurrent FSGS among patients at high risk for recurrence [<a href="#rid68">68,69</a>], larger studies have not confirmed these findings. As an example, in an observational study of 66 patients with primary FSGS, recurrent FSGS developed in 23 of 37 (62 percent) who received perioperative plasmapheresis with or without rituximab compared with 14 of 27 (51 percent) who did not receive any therapy [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H1703737249"><span class="h2">Treatment</span></p><p class="headingAnchor" id="H594207986"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>The optimal approach to therapy of patients with recurrent primary FSGS is not known, and treatment strategies vary among transplant centers. Our approach to initial therapy is determined by the timing of recurrence  (<a class="graphic graphic_algorithm graphicRef131825" href="/z/d/graphic/131825.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2349438969"><span class="h4">Early recurrence (≤3 months posttransplantation)</span><span class="headingEndMark"> — </span>Most patients with recurrent primary FSGS in the kidney allograft present early (within the first three months) after transplantation. (See <a class="local">'Clinical manifestations'</a> above.)</p><p>For patients with recurrent primary FSGS who present within the first three months of transplantation, we suggest treatment with plasmapheresis  (<a class="graphic graphic_algorithm graphicRef131825" href="/z/d/graphic/131825.html" rel="external">algorithm 1</a>). It is hypothesized that recurrent primary FSGS that occurs within a short time after transplantation is caused by a circulating permeability factor (see <a class="local">'Pathogenesis'</a> above), which could theoretically be removed by plasmapheresis. Some contributors to this topic also administer <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in combination with plasmapheresis, based upon observational data showing a possible benefit with combination therapy and a trend toward more relapses when plasmapheresis is performed without rituximab [<a href="#rid56">56</a>]. However, other contributors administer plasmapheresis alone, based upon the lack of clear evidence of benefit with use of rituximab in this setting [<a href="#rid13">13</a>], and reserve the use of rituximab for patients who do not respond to plasmapheresis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasmapheresis regimen</strong> – We initiate plasmapheresis early after the onset of recurrent disease. The optimal plasmapheresis regimen for the management of recurrent FSGS is unclear. Details to consider include the plasma volume to be replaced (1 versus 1.5 plasma volumes), choice of replacement fluid (albumin versus fresh frozen plasma [FFP]), and frequency of therapy. A typical plasmapheresis regimen is 1.5 plasma volume exchanges every other day for a total of two weeks using 5 percent albumin as the replacement solution. The need for further plasmapheresis is determined by the assessed response to therapy. (See <a class="local">'Monitoring and modifying therapy'</a> below.)</p><p></p><p class="bulletIndent1">In general, albumin is given as the replacement fluid. If, however, the patient has had a recent kidney biopsy, then one or two units of FFP should be substituted for albumin at the end of the procedure to replete coagulation factors that may have been depleted by plasmapheresis. Some experts routinely administer a small dose of intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>; ie, 150 to 200 mg/kg) after plasmapheresis sessions to replace depleted antibodies [<a href="#rid56">56</a>], whereas others give IVIG only if there is evidence of or concern for infection. (See  <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing of </strong><strong>rituximab</strong> – If <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is used, we administer rituximab 375 mg/m<sup>2</sup> for one to two doses [<a href="#rid13">13,56</a>]. Rituximab is typically given immediately after a plasmapheresis session, and plasmapheresis should be skipped the following day to avoid removing a significant amount of rituximab with plasmapheresis [<a href="#rid70">70,71</a>]. Some experts wait until the initial two-week course of plasmapheresis has been completed before administering rituximab. The optimal timing and dose of rituximab are unclear.</p><p></p><p>There are no randomized trials evaluating the use of plasmapheresis with or without <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> for recurrent primary FSGS. Observational studies in adults and children have suggested that plasmapheresis may induce remission of proteinuria in selected patients with recurrent FSGS [<a href="#rid1">1,5,38,40,41,56,72-81</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In the multicenter TANGO study of adults (age ≥16 years) with recurrent FSGS, treatment with plasmapheresis with or without <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> was the most frequently used therapy (61 of 75 patients [81 percent]) [<a href="#rid1">1</a>]. Thirty-two patients received both plasmapheresis and rituximab, 25 received only plasmapheresis, and three received only rituximab. Plasmapheresis with or without rituximab was associated with complete remission in 13 patients (21 percent), partial remission in 22 (36 percent), and no response in 26 (43 percent). Two of the patients who achieved complete remission experienced disease relapse that was responsive to repeat treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another observational study of 38 adults with recurrent FSGS who received treatment with plasmapheresis, 20 (50 percent) received additional <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid56">56</a>]. All but five patients (87 percent) responded to therapy (defined as a &gt;50 percent decrease in proteinuria); four patients, all of whom did not receive rituximab, experienced graft loss due to recurrent FSGS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One literature review found that 70 percent of children and 63 percent of adults with recurrent FSGS achieved complete or partial remission of proteinuria with plasmapheresis [<a href="#rid82">82</a>]. However, these studies, most of which were small, uncontrolled, and had short-term follow-up, may overestimate the benefit of plasmapheresis.</p><p></p><p>There are no data directly comparing plasmapheresis with other therapies, and it is unclear whether the combination of plasmapheresis plus <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is more effective than plasmapheresis alone. In one retrospective study of 148 adults with recurrent primary FSGS, rates of complete or partial remission were not significantly different between patients who received rituximab plus standard-of-care therapy (which included plasmapheresis, glucocorticoids, and calcineurin inhibitors) and those who received standard-of-care therapy alone [<a href="#rid13">13</a>]. However, the addition of rituximab may be beneficial for patients who do not respond to initial therapy with plasmapheresis alone [<a href="#rid13">13,80</a>]. (See <a class="local">'Resistant disease'</a> below.)</p><p class="headingAnchor" id="H1860318765"><span class="h4">Later recurrence (&gt;3 months posttransplantation)</span><span class="headingEndMark"> — </span>Less commonly, primary FSGS may recur later (beyond three months) after transplantation. In patients presenting with later recurrence, it is particularly important to distinguish true recurrent primary FSGS from secondary causes of FSGS, which are unlikely to respond to therapies used to treat recurrent primary FSGS  (<a class="graphic graphic_algorithm graphicRef131825" href="/z/d/graphic/131825.html" rel="external">algorithm 1</a>). (See <a class="local">'Early recurrence (≤3 months posttransplantation)'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>In patients without an identifiable cause of secondary FSGS, we suggest treatment with plasmapheresis, as discussed above for patients with early recurrence. (See <a class="local">'Early recurrence (≤3 months posttransplantation)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with an identifiable cause of secondary FSGS, we first administer therapy directed against the underlying cause since resolution of the FSGS usually occurs after addressing the underlying cause. As examples, patients with evidence of a viral infection that may cause FSGS should be treated for the viral infection, if possible. Patients who are taking a medication that is known to be associated with FSGS should discontinue this agent to see if proteinuria responds. If the patient does not achieve at least a partial remission (reduction in proteinuria ≥50 percent to a level between 0.3 and 3.5 g/day) with treatment of the underlying cause, we suggest treatment with plasmapheresis, as discussed above for patients with early recurrence. (See <a class="local">'Early recurrence (≤3 months posttransplantation)'</a> above.) </p><p></p><p class="headingAnchor" id="H3519253512"><span class="h4">Monitoring and modifying therapy</span><span class="headingEndMark"> — </span>In patients receiving treatment with plasmapheresis (with or without <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>), we obtain a spot urine protein-to-creatinine ratio after completion of plasmapheresis and then at weekly intervals to assess the response to therapy. We use the following definitions of response [<a href="#rid1">1,83</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A complete response is a reduction in proteinuria to &lt;0.3 g/day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A partial response is a reduction in proteinuria of ≥50 percent to a level between 0.3 and 3.5 g/day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No response is defined as not meeting either of the above two criteria.</p><p></p><p>Based upon these parameters, we determine the clinical response after <strong>two weeks</strong> of plasmapheresis and modify treatment as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who achieve a complete response, some contributors to this topic would discontinue plasmapheresis (and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, if administered) and continue to monitor the patient at weekly intervals for two to three months, then monthly to one year, and then every one to three months thereafter. However, other contributors would continue plasmapheresis weekly for a total duration of three months to try to prevent disease relapse. (See <a class="local">'Relapsing disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who achieve a partial response, most contributors of this topic would continue plasmapheresis, but clinical approaches vary among contributors. Some contributors would continue plasmapheresis once every two to three weeks for as long as the patient is tolerating the treatment without complications and proteinuria continues to improve. If the patient achieves a complete response, plasmapheresis is then discontinued.</p><p></p><p class="bulletIndent1">Other contributors would continue plasmapheresis weekly for a total treatment duration of at least three months, as they would for patients who achieve a complete response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who do not respond to initial therapy, we discontinue plasmapheresis. Such patients are considered to have resistant disease and may require treatment with alternative therapies to attain remission. (See <a class="local">'Resistant disease'</a> below.)</p><p></p><p class="headingAnchor" id="H3436770714"><span class="h4">General supportive measures</span><span class="headingEndMark"> — </span>General supportive measures in all patients with recurrent FSGS include dietary sodium and protein restriction, blood pressure control, minimization of proteinuria with renin-angiotensin system inhibition, and treatment of dyslipidemia. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, which have kidney protective benefits in patients with proteinuric chronic kidney disease (with or without diabetes), may also be of benefit in patients with recurrent FSGS, although studies in this patient population are lacking. Other aspects of therapy include diuretics to control edema and maintenance of adequate nutrition [<a href="#rid84">84</a>]. These measures are similar to those used in patients with glomerular disease involving the native kidneys and are discussed in greater detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Dietary sodium and protein restriction (see  <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Salt intake'</a> and  <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Protein intake'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antihypertensive therapy (see  <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">"Hypertension after kidney transplantation"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renin-angiotensin system inhibition (see  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Renin-angiotensin system inhibitors'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SGLT2 inhibitors (see  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Patients with proteinuria'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lipid lowering (see  <a class="medical medical_review" href="/z/d/html/7303.html" rel="external">"Lipid abnormalities after kidney transplantation"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of edema (see  <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults", section on 'Volume overload'</a>)</p><p></p><p class="headingAnchor" id="H74482335"><span class="h3">Relapsing disease</span><span class="headingEndMark"> — </span>Disease relapse (defined as a return of proteinuria to ≥3.5 g/day in someone who has undergone a complete or partial remission) may occur after a successful response to initial treatment. In one study, for example, 14 of 35 of patients (40 percent) who received initial treatment with plasmapheresis with or without <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> developed at least one relapse, and two lost their allograft [<a href="#rid56">56</a>]. In patients who develop a relapse after responding to initial therapy, we suggest repeat treatment with plasmapheresis, using the same approach as that used to treat the initial recurrence. Some patients with relapsing disease may require long-term plasmapheresis titrated to proteinuria levels. (See <a class="local">'Early recurrence (≤3 months posttransplantation)'</a> above.)</p><p>There are limited data to guide the optimal treatment of disease relapse. In the TANGO study cited above, two of the patients treated with plasmapheresis and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> who achieved complete remission experienced disease relapse that was responsive to repeat treatment [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1084871507"><span class="h3">Resistant disease</span><span class="headingEndMark"> — </span>The optimal treatment of patients with recurrent FSGS who do not respond to initial therapy with plasmapheresis (with or without <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) is unknown. Although a number of different therapeutic strategies have been tried, none have been shown to provide a clear benefit. In patients who do not respond to plasmapheresis alone, we suggest combination therapy with plasmapheresis and rituximab since the addition of rituximab in such patients has been shown to be beneficial in some series [<a href="#rid13">13,80</a>]. In patients who do not respond to plasmapheresis with rituximab, we suggest treatment with adrenocorticotropic hormone (ACTH) gel, although evidence in support of this approach is limited.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACTH gel</strong> – ACTH gel has been used with variable success in patients with primary FSGS of the native kidneys that is resistant to conventional therapies (see  <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Adrenocorticotropic hormone (ACTH)'</a>). In one report of 20 transplant recipients with recurrent or de novo FSGS resistant to conventional therapy with plasmapheresis and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, treatment with ACTH gel reduced mean proteinuria from 8.6 g/g to 3.3 g/g, and 10 patients (50 percent) achieved complete or partial remission [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipid apheresis</strong> – Lipid apheresis has been used as a therapy for children and adults with resistant nephrotic syndrome, including primary FSGS [<a href="#rid86">86,87</a>]. In one case series of seven children with recurrent FSGS presenting early (within hours to days) posttransplantation, treatment with lipid apheresis and pulse <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> resulted in partial or complete remission of proteinuria in all patients [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abatacept</strong> – <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">Abatacept</a> is a soluble fusion protein that inhibits the T cell protein, B7-1 (CD80) and has been used for the treatment of rheumatoid arthritis and other rheumatologic conditions. Although an initial report suggested benefit with the use of abatacept among patients with recurrent idiopathic FSGS [<a href="#rid89">89</a>], other studies evaluating the use of abatacept or <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">belatacept</a>, a B7-1 blocker with higher affinity, for recurrent FSGS have not demonstrated a benefit [<a href="#rid90">90-93</a>]. (See  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'Methotrexate plus abatacept'</a> and  <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Abatacept'</a>.)</p><p></p><p class="headingAnchor" id="H2048171045"><span class="h3">Recurrent genetic FSGS</span><span class="headingEndMark"> — </span>Recurrence of genetic FSGS is rare but has been reported in the patients with homozygous or compound heterozygous podocin mutations (see <a class="local">'Epidemiology and risk factors'</a> above). The optimal treatment of such patients is not known. We would treat such patients using the same approach used to treat patients with recurrent primary FSGS since these patients may respond to aggressive therapy (plasmapheresis with or without immunosuppressive therapy) [<a href="#rid26">26-30</a>]. (See <a class="local">'Early recurrence (≤3 months posttransplantation)'</a> above.)</p><p class="headingAnchor" id="H3850660890"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Among patients with FSGS as a cause of ESKD in the native kidney, recurrent FSGS may result in allograft loss in a significant number of patients:</p><p class="bulletIndent1"><span class="glyph">●</span>In the multicenter TANGO cohort study of 176 transplant recipients with biopsy-proven primary FSGS as the cause of ESKD, graft loss occurred in 39 percent of patients with recurrent FSGS, compared with 15 percent of those without recurrence, over a median of five years [<a href="#rid1">1</a>]. Graft loss occurred mainly in patients in whom remission could not be achieved, and the median time from recurrence to graft loss was seven months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of 736 kidney transplant recipients (666 adults and 70 children) in the Australia and New Zealand Dialysis and Transplant Registry with a history of ESKD due to biopsy-proven primary FSGS, those with recurrent disease posttransplantation had higher rates of graft loss at five years compared with those without recurrent disease (48 versus 17 percent) [<a href="#rid17">17</a>]. The majority of graft loss occurred in the first two years after disease recurrence.</p><p></p><p>The prognosis of recurrent secondary FSGS depends upon the underlying cause. In the native kidney, viral-induced FSGS tends to progress to ESKD, whereas FSGS related to hyperfiltration and obesity usually follows a more indolent course. Virtually no studies have examined prognosis of specific types of FSGS in the allograft, but one would expect that FSGS would carry a worse prognosis in a transplanted kidney, compared with a native kidney, given the lower number of functioning nephrons available to sustain glomerular filtration rate (GFR). (See  <a class="medical medical_review" href="/z/d/html/3080.html" rel="external">"Collapsing focal segmental glomerulosclerosis (collapsing glomerulopathy)", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H3104828377"><span class="h2">Retransplantation</span><span class="headingEndMark"> — </span>Patients who develop recurrent disease in the first transplant are at very high risk (up to 75 percent) for recurrence in subsequent allografts [<a href="#rid7">7,8</a>]. Graft loss due to recurrent disease is seen in 10 to 80 percent of these patients, with the prognosis being worse in patients with persistent nephrotic syndrome [<a href="#rid5">5-7</a>].</p><p>Some clinicians have suggested that, if a first graft is lost to recurrent disease, a second transplant should be delayed for one to two years or avoided completely [<a href="#rid94">94</a>]. This delay, which may be most appropriate if recurrence is rapid, may result in the disappearance of the circulating nephrotoxic factors that are responsible for the glomerular injury. However, the efficacy of this approach is not proven. A third transplant in patients with two previous transplant losses due to recurrent FSGS should generally be avoided, especially if both prior graft losses occurred soon after transplantation with no response to extensive treatment.</p><p class="headingAnchor" id="H3744658901"><span class="h1">DE NOVO FSGS</span><span class="headingEndMark"> — </span>Some patients develop primary or secondary focal segmental glomerulosclerosis (FSGS) in the transplanted kidney even though they did not have FSGS in their native kidneys:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and risk factors</strong> – The incidence of de novo FSGS is difficult to estimate since the cause of end-stage kidney disease (ESKD) in the native kidney is unknown among many transplant recipients. In one study of 4913 transplant recipients, 57 patients developed biopsy-demonstrated FSGS in the transplanted kidney at a follow-up of 1.8 years; of these, 30 (53 percent) had known FSGS in the native kidney, and 27 (47 percent) did not have a kidney biopsy of the native kidney [<a href="#rid95">95</a>]. From these data, one can estimate that new FSGS develops in &lt;0.6 percent of allografts since at least some of the patients in this group probably had undiagnosed FSGS in the native kidney. However, because of the relatively limited follow-up (less than two years), this study underestimated the rate of incidence of new-onset secondary FSGS related to hyperfiltration injury, which generally takes longer to develop.</p><p></p><p class="bulletIndent1">Recipients of kidney transplants from donors with <em>APOL1 </em>high-risk alleles have been shown to have an increased risk of de novo collapsing FSGS in the allograft [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The pathogenesis of de novo primary FSGS in the transplanted kidney is likely the same as that in the native kidney [<a href="#rid97">97,98</a>]. In addition, any of the causes of FSGS in the native kidney may also occur in the allograft; these include infections, toxins, or obesity. These issues are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis", section on 'Pathogenesis of primary FSGS'</a> and  <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis", section on 'Pathogenesis of secondary FSGS'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – In contrast with patients with recurrent primary FSGS, patients who develop de novo FSGS generally present much later; among such patients, the onset of proteinuria generally occurs three months or more after transplantation. However, rapidly progressive graft failure can occur among patients with de novo FSGS of collapsing subtype [<a href="#rid97">97-99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of de novo FSGS should be suspected in any kidney transplant recipient who presents with the new onset of proteinuria &gt;1 g/day after transplantation. A kidney allograft biopsy is required to make a definitive diagnosis. Once the diagnosis of FSGS is confirmed by kidney allograft biopsy, an evaluation for causes of secondary FSGS  (<a class="graphic graphic_table graphicRef118939" href="/z/d/graphic/118939.html" rel="external">table 1</a>) should be performed since histologic features do not reliably distinguish between primary and secondary FSGS and there is significant overlap in the clinical features. Patients without an identifiable secondary cause are considered to have de novo primary FSGS. (See  <a class="medical medical_review" href="/z/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction", section on 'Patients presenting with proteinuria'</a> and <a class="local">'Evaluation for secondary causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – In kidney transplant recipients with de novo FSGS, the approach to treatment depends upon whether the patient is considered to have primary or secondary FSGS:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with de novo primary FSGS are treated as patients with recurrent primary FSGS. The rationale for this approach is that many patients with apparent de novo primary FSGS, especially those whose cause of ESKD in the native kidneys was not confirmed, may actually have recurrent FSGS. In patients whose cause of ESKD is known and who have de novo primary FSGS, treating for recurrent FSGS may also be reasonable since such patients have developed FSGS in the setting of already receiving immunosuppression with calcineurin inhibitors, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>, and glucocorticoids, agents that are frequently used to treat primary FSGS in the native kidneys. However, there is no high-quality evidence to support this approach. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with an identifiable secondary cause for FSGS (eg, viral infection, toxin) should receive therapy directed at the underlying cause since this usually leads to resolution of the FSGS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The prognosis of de novo primary FSGS is generally poor; untreated primary FSGS often follows a progressive course to ESKD. The rate of spontaneous, complete remission among patients with nephrotic syndrome is unknown but is probably &lt;10 percent. This is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Prognosis'</a>.)</p><p></p><p class="headingAnchor" id="H178554901"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">"Society guideline links: Kidney transplantation"</a>.)</p><p class="headingAnchor" id="H2079164946"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Focal segmental glomerulosclerosis (FSGS) is a histologic pattern of injury in the kidney that may have different etiologies, including genetic diseases, infection, toxins, and obesity, as well as previous injury resulting in hyperfiltration of remaining viable nephrons. Primary FSGS, which occurs in the absence of a known etiology, commonly progresses to end-stage kidney disease (ESKD). When kidney transplantation is performed, primary FSGS may recur in the kidney allograft. Some patients develop de novo FSGS in the transplanted kidney even though they did not have FSGS in their native kidneys. (See <a class="local">'Introduction'</a> above and <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent FSGS</strong> – Recurrent FSGS refers to the development of primary FSGS in the transplanted kidney in patients with primary FSGS as the cause of ESKD in the native kidneys. Recurrent primary FSGS is likely due to a circulating factor or the absence of a normal factor present in plasma, with either resulting in toxicity to the podocyte or glomerular capillary wall. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical manifestations</strong> – Patients with recurrent primary FSGS typically present with the rapid onset of proteinuria, which is frequently in the nephrotic range, in the immediate to early posttransplantation period. In children, the median time to recurrent proteinuria is approximately 10 to 14 days after transplantation, while in adults, the median time to recurrence is approximately 1.5 months. Less commonly, patients with recurrent primary FSGS may present later (several months or years) after transplantation. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Posttransplantation surveillance</strong> – To help detect early recurrence posttransplantation, all patients with primary FSGS as the cause of ESKD in the native kidneys should be screened for proteinuria. We obtain a random or spot urine protein-to-creatinine ratio on the first postoperative day, the day of scheduled hospital discharge, weekly for four weeks, and then monthly for one year after transplantation. If the ratio is &gt;0.5 g/g, we obtain a 24-hour protein collection to confirm the result obtained with the random urine protein-to-creatinine ratio. (See <a class="local">'Posttransplantation surveillance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnostic evaluation</strong> – The diagnosis of recurrent FSGS should be suspected in any patient with primary FSGS as the cause of ESKD in the native kidneys who presents with proteinuria greater than 1 g/day detected by routine screening or who develops symptoms and signs of nephrotic syndrome. Such patients should undergo a kidney allograft biopsy to confirm the diagnosis of FSGS. Patients who are diagnosed with FSGS by allograft biopsy should be evaluated for possible underlying causes and associated conditions since clinical and histologic features alone cannot distinguish recurrent primary from de novo secondary FSGS with certainty. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention</strong> – In patients with primary FSGS as the cause of ESKD in the native kidneys, we do not administer any prophylactic measures to prevent recurrent FSGS. Although such patients may be at high risk of recurrence, the use of preventive measures (such as plasmapheresis or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) in these patients has not been clearly shown to reduce rates of recurrence. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment</strong> – The optimal approach to therapy of patients with recurrent primary FSGS is not known, and treatment strategies vary among transplant centers. Our approach to initial therapy is determined by the timing of recurrence  (<a class="graphic graphic_algorithm graphicRef131825" href="/z/d/graphic/131825.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Early recurrence</strong> – For patients with recurrent primary FSGS who present within the first three months of transplantation, we suggest treatment with plasmapheresis, rather than <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> monotherapy, adrenocorticotropic hormone (ACTH) gel, or other therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Some, but not all, contributors to this topic administer plasmapheresis in combination with rituximab. (See <a class="local">'Early recurrence (≤3 months posttransplantation)'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Later recurrence</strong> – For patients presenting with later recurrence (&gt;3 months after transplantation), it is particularly important to distinguish true recurrent primary FSGS from secondary causes of FSGS, which are unlikely to respond to therapies used to treat recurrent primary FSGS. In patients without an identifiable cause of secondary FSGS, we suggest treatment with plasmapheresis rather than other therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In patients with an identifiable cause of secondary FSGS, we first administer therapy directed against the underlying cause. If proteinuria does not improve with treatment of the underlying cause, we administer plasmapheresis. (See <a class="local">'Later recurrence (&gt;3 months posttransplantation)'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>General supportive measures</strong> – General supportive measures in all patients with recurrent FSGS include dietary sodium and protein restriction, blood pressure control, minimization of proteinuria with renin-angiotensin system inhibition, and treatment of dyslipidemia. Other aspects of therapy include diuretics to control edema and maintenance of adequate nutrition. (See <a class="local">'General supportive measures'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Relapsing disease</strong> – For patients who develop a relapse after responding to initial therapy, we suggest repeat treatment with plasmapheresis rather than switching to an alternative therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Some patients with relapsing disease may require long-term plasmapheresis titrated to proteinuria levels. (See <a class="local">'Relapsing disease'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Resistant disease</strong> – For patients with recurrent primary FSGS who do not respond to initial therapy with plasmapheresis alone, we suggest combination therapy with plasmapheresis and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with recurrent primary FSGS who do not respond to therapy with plasmapheresis and rituximab, we suggest ACTH gel rather than lipid apheresis or other therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Evidence in support of this approach is limited. (See <a class="local">'Resistant disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>De novo FSGS</strong> – De novo FSGS is the development of primary or secondary FSGS in the transplanted kidney in patients who did not have FSGS in their native kidneys. In contrast with patients with recurrent primary FSGS, patients who develop de novo FSGS generally present much later; among such patients, the onset of proteinuria generally occurs three months or more after transplantation. The diagnosis of de novo FSGS should be suspected in any kidney transplant recipient who presents with the new onset of proteinuria &gt;1 g/day after transplantation; a kidney allograft biopsy is required to make a definitive diagnosis. Patients with de novo primary FSGS are treated as patients with recurrent primary FSGS. Patients with an identifiable secondary cause for FSGS (eg, viral infection, toxin) should receive therapy directed at the underlying cause. (See <a class="local">'De novo FSGS'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Uffing A, Pérez-Sáez MJ, Mazzali M, et al. Recurrence of FSGS after Kidney Transplantation in Adults. Clin J Am Soc Nephrol 2020; 15:247.</a></li><li><a class="nounderline abstract_t">Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6:2535.</a></li><li><a class="nounderline abstract_t">Cheigh JS, Mouradian J, Susin M, et al. Kidney transplant nephrotic syndrome: relationship between allograft histopathology and natural course. Kidney Int 1980; 18:358.</a></li><li><a class="nounderline abstract_t">Kim EM, Striegel J, Kim Y, et al. Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection. Kidney Int 1994; 45:1440.</a></li><li><a class="nounderline abstract_t">Pinto J, Lacerda G, Cameron JS, et al. Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation 1981; 32:83.</a></li><li><a class="nounderline abstract_t">Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992; 2:S258.</a></li><li><a class="nounderline abstract_t">Striegel JE, Sibley RK, Fryd DS, Mauer SM. Recurrence of focal segmental sclerosis in children following renal transplantation. Kidney Int Suppl 1986; 19:S44.</a></li><li><a class="nounderline abstract_t">Lewis EJ. Recurrent focal sclerosis after renal transplantation. Kidney Int 1982; 22:315.</a></li><li><a class="nounderline abstract_t">Abbott KC, Sawyers ES, Oliver JD 3rd, et al. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 2001; 37:366.</a></li><li><a class="nounderline abstract_t">Chadban S. Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol 2001; 12:394.</a></li><li><a class="nounderline abstract_t">Ghiggeri GM, Carraro M, Vincenti F. Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant 2004; 19:1036.</a></li><li><a class="nounderline abstract_t">Ding WY, Koziell A, McCarthy HJ, et al. Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence. J Am Soc Nephrol 2014; 25:1342.</a></li><li><a class="nounderline abstract_t">Lanaret C, Anglicheau D, Audard V, et al. Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. Am J Transplant 2021; 21:3021.</a></li><li><a class="nounderline abstract_t">Dantal J, Baatard R, Hourmant M, et al. Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis. A one-center study of plasma exchange effects. Transplantation 1991; 52:827.</a></li><li><a class="nounderline abstract_t">Shimizu A, Higo S, Fujita E, et al. Focal segmental glomerulosclerosis after renal transplantation. Clin Transplant 2011; 25 Suppl 23:6.</a></li><li><a class="nounderline abstract_t">Nehus EJ, Goebel JW, Succop PS, Abraham EC. Focal segmental glomerulosclerosis in children: multivariate analysis indicates that donor type does not alter recurrence risk. Transplantation 2013; 96:550.</a></li><li><a class="nounderline abstract_t">Francis A, Trnka P, McTaggart SJ. Long-Term Outcome of Kidney Transplantation in Recipients with Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 2016; 11:2041.</a></li><li><a class="nounderline abstract_t">Conlon PJ, Lynn K, Winn MP, et al. Spectrum of disease in familial focal and segmental glomerulosclerosis. Kidney Int 1999; 56:1863.</a></li><li><a class="nounderline abstract_t">Felldin M, Nordén G, Svalander C, Nyberg G. Focal segmental glomerulosclerosis in a kidney transplant population: hereditary and sporadic forms. Transpl Int 1998; 11:16.</a></li><li><a class="nounderline abstract_t">Carraro M, Caridi G, Bruschi M, et al. Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13:1946.</a></li><li><a class="nounderline abstract_t">Bertelli R, Ginevri F, Caridi G, et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003; 41:1314.</a></li><li><a class="nounderline abstract_t">Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15:722.</a></li><li><a class="nounderline abstract_t">Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004; 66:571.</a></li><li><a class="nounderline abstract_t">Jungraithmayr TC, Hofer K, Cochat P, et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J Am Soc Nephrol 2011; 22:579.</a></li><li><a class="nounderline abstract_t">Schachter ME, Monahan M, Radhakrishnan J, et al. Recurrent focal segmental glomerulosclerosis in the renal allograft: single center experience in the era of modern immunosuppression. Clin Nephrol 2010; 74:173.</a></li><li><a class="nounderline abstract_t">Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175.</a></li><li><a class="nounderline abstract_t">Tzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128:345.</a></li><li><a class="nounderline abstract_t">Freedman BI, Kopp JB, Langefeld CD, et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010; 21:1422.</a></li><li><a class="nounderline abstract_t">Pollak MR. Kidney disease and African ancestry. Nat Genet 2008; 40:1145.</a></li><li><a class="nounderline abstract_t">Babayeva S, Miller M, Zilber Y, et al. Plasma from a case of recurrent idiopathic FSGS perturbs non-muscle myosin IIA (MYH9 protein) in human podocytes. Pediatr Nephrol 2011; 26:1071.</a></li><li><a class="nounderline abstract_t">Lee BT, Kumar V, Williams TA, et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012; 12:1924.</a></li><li><a class="nounderline abstract_t">Roy N, Morales-Alvarez MC, Anis KH, et al. Association of Recipient APOL1 Kidney Risk Alleles With Kidney Transplant Outcomes. Transplantation 2023; 107:2575.</a></li><li><a class="nounderline abstract_t">Zhang Z, Sun Z, Fu J, et al. Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes. J Clin Invest 2021; 131.</a></li><li><a class="nounderline abstract_t">IJpelaar DH, Farris AB, Goemaere N, et al. Fidelity and evolution of recurrent FSGS in renal allografts. J Am Soc Nephrol 2008; 19:2219.</a></li><li><a class="nounderline abstract_t">Canaud G, Dion D, Zuber J, et al. Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 2010; 25:1321.</a></li><li><a class="nounderline abstract_t">Fuentes GM, Meseguer CG, Carrion AP, et al. Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation. Pediatr Nephrol 2010; 25:529.</a></li><li><a class="nounderline abstract_t">Pham PT, Pham PC. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Nephrol Dial Transplant 2012; 27:2965.</a></li><li><a class="nounderline abstract_t">Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334:878.</a></li><li><a class="nounderline abstract_t">Dall'Amico R, Ghiggeri G, Carraro M, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999; 34:1048.</a></li><li><a class="nounderline abstract_t">Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330:7.</a></li><li><a class="nounderline abstract_t">Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994; 23:574.</a></li><li><a class="nounderline abstract_t">Sharma M, Sharma R, McCarthy ET, Savin VJ. "The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999; 10:552.</a></li><li><a class="nounderline abstract_t">Sharma M, Sharma R, Reddy SR, et al. Proteinuria after injection of human focal segmental glomerulosclerosis factor. Transplantation 2002; 73:366.</a></li><li><a class="nounderline abstract_t">Candiano G, Musante L, Carraro M, et al. Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis. J Am Soc Nephrol 2001; 12:143.</a></li><li><a class="nounderline abstract_t">Gallon L, Leventhal J, Skaro A, et al. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 2012; 366:1648.</a></li><li><a class="nounderline abstract_t">Hamroun A, Gibier JB, Maanaoui M, et al. Successful Reuse of Kidney Graft After Early Recurrence of Primary Focal and Segmental Glomerulosclerosis. Am J Kidney Dis 2021; 78:897.</a></li><li><a class="nounderline abstract_t">Kienzl-Wagner K, Rosales A, Scheidl S, et al. Successful management of recurrent focal segmental glomerulosclerosis. Am J Transplant 2018; 18:2818.</a></li><li><a class="nounderline abstract_t">Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17:952.</a></li><li><a class="nounderline abstract_t">Alachkar N, Li J, Matar D, et al. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab. BMC Nephrol 2018; 19:361.</a></li><li><a class="nounderline abstract_t">Delville M, Sigdel TK, Wei C, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med 2014; 6:256ra136.</a></li><li><a class="nounderline abstract_t">Jacobs-Cachá C, Puig-Gay N, Helm D, et al. A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis. Sci Rep 2020; 10:1159.</a></li><li><a class="nounderline abstract_t">Shirai Y, Miura K, Ishizuka K, et al. A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence. Kidney Int 2023.</a></li><li><a class="nounderline abstract_t">Kachurina N, Chung CF, Benderoff E, et al. Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis. Am J Physiol Renal Physiol 2016; 310:F1148.</a></li><li><a class="nounderline abstract_t">Leroy S, Guigonis V, Bruckner D, et al. Successful anti-TNFalpha treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis. Am J Transplant 2009; 9:858.</a></li><li><a class="nounderline abstract_t">Bitzan M, Babayeva S, Vasudevan A, et al. TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation. Pediatr Nephrol 2012; 27:2217.</a></li><li><a class="nounderline abstract_t">Alasfar S, Matar D, Montgomery RA, et al. Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation. Transplantation 2018; 102:e115.</a></li><li><a class="nounderline abstract_t">Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005; 5:1179.</a></li><li><a class="nounderline abstract_t">D'Cunha PT, Parasuraman R, Venkat KK. Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation. Am J Transplant 2005; 5:351.</a></li><li><a class="nounderline abstract_t">Myslak M, Amer H, Morales P, et al. Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant 2006; 6:1660.</a></li><li><a class="nounderline abstract_t">Goh BK, Dean PG, Cosio FG, et al. Bilateral native ureteral ligation without nephrectomy in the management of kidney transplant recipients with native proteinuria. Am J Transplant 2011; 11:2747.</a></li><li><a class="nounderline abstract_t">Lopez-Hellin J, Cantarell C, Jimeno L, et al. A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation. Am J Transplant 2013; 13:493.</a></li><li><a class="nounderline abstract_t">Puig-Gay N, Jacobs-Cacha C, Sellarès J, et al. Apolipoprotein A-Ib as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value - a multi-centre cohort study. Transpl Int 2019; 32:313.</a></li><li><a class="nounderline abstract_t">Alachkar N, Wei C, Arend LJ, et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation 2013; 96:649.</a></li><li><a class="nounderline abstract_t">Laboux T, Gibier JB, Pottier N, et al. COVID-19-related collapsing glomerulopathy revealing a rare risk variant of APOL1: lessons for the clinical nephrologist. J Nephrol 2021; 34:373.</a></li><li><a class="nounderline abstract_t">Doevelaar AAN, Hölzer B, Seibert FS, et al. Lessons for the clinical nephrologist: recurrence of nephrotic syndrome induced by SARS-CoV-2. J Nephrol 2020; 33:1369.</a></li><li><a class="nounderline abstract_t">Mawhorter S, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13:581.</a></li><li><a class="nounderline abstract_t">Boddana P, Webb LH, Unsworth J, et al. Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon? Clin Transplant 2011; 25:417.</a></li><li><a class="nounderline abstract_t">Meyer TN, Thaiss F, Stahl RA. Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 2007; 20:1066.</a></li><li><a class="nounderline abstract_t">Gohh RY, Yango AF, Morrissey PE, et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005; 5:2907.</a></li><li><a class="nounderline abstract_t">Puisset F, White-Koning M, Kamar N, et al. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 2013; 76:734.</a></li><li><a class="nounderline abstract_t">Darabi K, Berg AH. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 2006; 125:592.</a></li><li><a class="nounderline abstract_t">Artero M, Biava C, Amend W, et al. Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med 1992; 92:375.</a></li><li><a class="nounderline abstract_t">Matalon A, Markowitz GS, Joseph RE, et al. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol 2001; 56:271.</a></li><li><a class="nounderline abstract_t">Laufer J, Ettenger RB, Ho WG, et al. Plasma exchange for recurrent nephrotic syndrome following renal transplantation. Transplantation 1988; 46:540.</a></li><li><a class="nounderline abstract_t">Cheong HI, Han HW, Park HW, et al. Early recurrent nephrotic syndrome after renal transplantation in children with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000; 15:78.</a></li><li><a class="nounderline abstract_t">Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87:1232.</a></li><li><a class="nounderline abstract_t">Canaud G, Zuber J, Sberro R, et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant 2009; 9:1081.</a></li><li><a class="nounderline abstract_t">Dudreuilh C, Barbet C, Gatault P, et al. Response to plasma exchange and graft survival in recurrent focal and segmental glomerulosclerosis after transplantation: does the time of recurrence matter? A retrospective study. Transpl Int 2021; 34:302.</a></li><li><a class="nounderline abstract_t">Weber LT, Tönshoff B, Grenda R, et al. Clinical practice recommendations for recurrence of focal and segmental glomerulosclerosis/steroid-resistant nephrotic syndrome. Pediatr Transplant 2021; 25:e13955.</a></li><li><a class="nounderline abstract_t">Dello Strologo L, Guzzo I, Laurenzi C, et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 2009; 88:417.</a></li><li><a class="nounderline abstract_t">Garrouste C, Canaud G, Büchler M, et al. Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes. Transplantation 2017; 101:649.</a></li><li><a class="nounderline abstract_t">Ponticelli C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant 2010; 25:25.</a></li><li><a class="nounderline abstract_t">Troost JP, Trachtman H, Nachman PH, et al. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 2018; 13:414.</a></li><li><a class="nounderline abstract_t">Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:268.</a></li><li><a class="nounderline abstract_t">Alhamad T, Manllo Dieck J, Younus U, et al. ACTH Gel in Resistant Focal Segmental Glomerulosclerosis After Kidney Transplantation. Transplantation 2019; 103:202.</a></li><li><a class="nounderline abstract_t">Hattori M, Chikamoto H, Akioka Y, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003; 42:1121.</a></li><li><a class="nounderline abstract_t">Muso E, Mune M, Hirano T, et al. Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clin Exp Nephrol 2015; 19:379.</a></li><li><a class="nounderline abstract_t">Shah L, Hooper DK, Okamura D, et al. LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients. Pediatr Nephrol 2019; 34:2343.</a></li><li><a class="nounderline abstract_t">Yu CC, Fornoni A, Weins A, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013; 369:2416.</a></li><li><a class="nounderline abstract_t">Alachkar N, Carter-Monroe N, Reiser J. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2014; 370:1263.</a></li><li><a class="nounderline abstract_t">Garin EH, Reiser J, Cara-Fuentes G, et al. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol 2015; 30:469.</a></li><li><a class="nounderline abstract_t">Alkandari O, Nampoory N, Nair P, et al. Recurrent Focal Segmental Glomerulosclerosis and Abatacept: Case Report. Exp Clin Transplant 2016; 14:456.</a></li><li><a class="nounderline abstract_t">Delville M, Baye E, Durrbach A, et al. B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS. J Am Soc Nephrol 2016; 27:2520.</a></li><li><a class="nounderline abstract_t">Hosenpud J, Piering WF, Garancis JC, Kauffman HM. Successful second kidney transplantation in a patient with focal glomerulosclerosis. A case report. Am J Nephrol 1985; 5:299.</a></li><li><a class="nounderline abstract_t">Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999; 68:635.</a></li><li><a class="nounderline abstract_t">Santoriello D, Husain SA, De Serres SA, et al. Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts. Kidney Int 2018; 94:1189.</a></li><li><a class="nounderline abstract_t">Meehan SM, Pascual M, Williams WW, et al. De novo collapsing glomerulopathy in renal allografts. Transplantation 1998; 65:1192.</a></li><li><a class="nounderline abstract_t">Stokes MB, Davis CL, Alpers CE. Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations. Am J Kidney Dis 1999; 33:658.</a></li><li><a class="nounderline abstract_t">Swaminathan S, Lager DJ, Qian X, et al. Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrol Dial Transplant 2006; 21:2607.</a></li></ol></div><div id="topicVersionRevision">Topic 7342 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31974287" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recurrence of FSGS after Kidney Transplantation in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16939521" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Recurrent glomerulonephritis after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7007710" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Kidney transplant nephrotic syndrome: relationship between allograft histopathology and natural course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8072257" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7027555" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recurrence of focal segmental glomerulosclerosis in renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1498285" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3528625" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Recurrence of focal segmental sclerosis in children following renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6757526" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Recurrent focal sclerosis after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157379" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11158232" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Glomerulonephritis recurrence in the renal graft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15004256" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24511128" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Initial steroid sensitivity in children with steroid-resistant nephrotic syndrome predicts post-transplant recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512779" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1949168" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis. A one-center study of plasma exchange effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21623907" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Focal segmental glomerulosclerosis after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23912170" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Focal segmental glomerulosclerosis in children: multivariate analysis indicates that donor type does not alter recurrence risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27797890" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-Term Outcome of Kidney Transplantation in Recipients with Focal Segmental Glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571795" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Spectrum of disease in familial focal and segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9503549" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Focal segmental glomerulosclerosis in a kidney transplant population: hereditary and sporadic forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12089392" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12776285" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14978175" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15253708" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21355056" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20860901" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recurrent focal segmental glomerulosclerosis in the renal allograft: single center experience in the era of modern immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794856" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20635188" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688934" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18818713" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Kidney disease and African ancestry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21380797" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Plasma from a case of recurrent idiopathic FSGS perturbs non-muscle myosin IIA (MYH9 protein) in human podocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22487534" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37527489" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Association of Recipient APOL1 Kidney Risk Alleles With Kidney Transplant Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34499625" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18579640" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fidelity and evolution of recurrent FSGS in renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19773419" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19956977" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22207327" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8596570" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585314" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8259160" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8154495" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073606" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : "The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11884932" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Proteinuria after injection of human focal segmental glomerulosclerosis factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134260" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22533598" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Resolution of recurrent focal segmental glomerulosclerosis after retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34118304" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Successful Reuse of Kidney Graft After Early Recurrence of Primary Focal and Segmental Glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29962080" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Successful management of recurrent focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21804539" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30558559" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25273097" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31980684" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38110152" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26719363" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344472" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Successful anti-TNFalpha treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22538781" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : TNFαpathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton andβ3 integrin activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29189487" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Rituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888021" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15643995" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16827868" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21883918" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Bilateral native ureteral ligation without nephrectomy in the management of kidney transplant recipients with native proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23205849" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30411406" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Apolipoprotein A-Ib as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value - a multi-centre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23842190" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33548053" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : COVID-19-related collapsing glomerulopathy revealing a rare risk variant of APOL1: lessons for the clinical nephrologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32892322" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Lessons for the clinical nephrologist: recurrence of nephrotic syndrome induced by SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19060546" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hypogammaglobulinemia and infection risk in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20438577" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17887957" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303004" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432476" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16627268" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558084" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Recurrent focal glomerulosclerosis: natural history and response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11680656" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3051560" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Plasma exchange for recurrent nephrotic syndrome following renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10607771" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Early recurrent nephrotic syndrome after renal transplantation in children with focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384172" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344432" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33275815" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Response to plasma exchange and graft survival in recurrent focal and segmental glomerulosclerosis after transplantation: does the time of recurrence matter? A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33378587" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical practice recommendations for recurrence of focal and segmental glomerulosclerosis/steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667947" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Use of rituximab in focal glomerulosclerosis relapses after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27043407" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19875378" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29167190" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30665568" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29894413" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : ACTH Gel in Resistant Focal Segmental Glomerulosclerosis After Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655182" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24934117" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31250206" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24206430" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Abatacept in B7-1-positive proteinuric kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24670180" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Abatacept in B7-1-positive proteinuric kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25239302" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25432003" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Recurrent Focal Segmental Glomerulosclerosis and Abatacept: Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26701979" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3901759" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Successful second kidney transplantation in a patient with focal glomerulosclerosis. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10507481" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30287079" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603167" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : De novo collapsing glomerulopathy in renal allografts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10196006" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16705026" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
